Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

PHASE4CompletedINTERVENTIONAL

Enrollment

127

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

RivaroxabanCancer-associated ThrombosisRecurrenceBleeding

Interventions

DRUG

Rivaroxaban

Rivaroxaban 15mg twice daily for the first 3 weeks, followed by 20mg once daily during 6 months

Trial Locations (1)

Seoul National University Bundang Hospital, Seongnam

All Listed Sponsors

collaborator

Korean Society of Hematology Thrombosis Working Party

UNKNOWN

lead

Seoul National University Hospital

OTHER

NCT01989845 - Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer | Biotech Hunter | Biotech Hunter